Mawatari, S.; Tamai, T.; Kumagai, K.; Saisyoji, A.; Muromachi, K.; Toyodome, A.; Taniyama, O.; Sakae, H.; Ijuin, S.; Tabu, K.;
et al. Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. Cancers 2022, 14, 6139.
https://doi.org/10.3390/cancers14246139
AMA Style
Mawatari S, Tamai T, Kumagai K, Saisyoji A, Muromachi K, Toyodome A, Taniyama O, Sakae H, Ijuin S, Tabu K,
et al. Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. Cancers. 2022; 14(24):6139.
https://doi.org/10.3390/cancers14246139
Chicago/Turabian Style
Mawatari, Seiichi, Tsutomu Tamai, Kotaro Kumagai, Akiko Saisyoji, Kaori Muromachi, Ai Toyodome, Ohki Taniyama, Haruka Sakae, Sho Ijuin, Kazuaki Tabu,
and et al. 2022. "Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma" Cancers 14, no. 24: 6139.
https://doi.org/10.3390/cancers14246139
APA Style
Mawatari, S., Tamai, T., Kumagai, K., Saisyoji, A., Muromachi, K., Toyodome, A., Taniyama, O., Sakae, H., Ijuin, S., Tabu, K., Oda, K., Hiramine, Y., Moriuchi, A., Sakurai, K., Kanmura, S., & Ido, A.
(2022). Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. Cancers, 14(24), 6139.
https://doi.org/10.3390/cancers14246139
